Navigation Links
Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
Date:10/28/2013

Ph.D., Chief Medical Officer for Juventas and Director of Research, Summa Cardiovascular Institute at Summa Health Systems. "The goal of STOP-HF is to further define the safety and clinical benefits of JVS-100 in heart failure patients who are already receiving the current standard of care."

Earlier this year, Juventas Therapeutics completed enrollment of STOP-CLI, a Phase IIa first-in-human, double-blinded, placebo-controlled, dose-escalation trial of JVS-100 for patients with Rutherford class 4 or 5 critical limb ischemia (CLI).  The 48-person trial enrolled CLI patients considered poor candidates for revascularization at four centers in the United States and two centers in India.  The primary endpoint for the trial will be safety with efficacy data collected on several key endpoints including amputation rates, Rutherford class, wound closure, and pain management.

"Completing enrollment of STOP-CLI and STOP-HF are significant milestones for the company this year," states Rahul Aras, Ph.D., President and CEO for Juventas Therapeutics.  "To date, more than 120 patients have received JVS-100 therapy and we are building a strong safety profile.  Next year is an important year for Juventas, with efficacy data results targeted from both Phase II studies and additional trials scheduled to enroll.  We are excited to transition JVS-100 into late stage clinical trials and commercialization."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, Ohio, is a privately-held clinical-stage biotechnology company developing therapies for cardiovascular disease. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include New Science Ventures, Triathlon Medical Ventu
'/>"/>

SOURCE Juventas Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
2. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
3. Aratana Therapeutics Adds to Commercial Leadership Team
4. Mirati Therapeutics Prices Public Offering Of Common Stock
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
6. Cell Therapeutics to Report Third Quarter Financial Results after Market on October 30, 2013
7. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
8. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Aratana Therapeutics names Wendy Yarno to its Board of Directors
10. PTC Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
11. Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... PLEASANTON, Calif. , July 21, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... will report its operating results for the second quarter ... The company will hold a conference call to ... all interested parties, at 1:30 p.m., Pacific Daylight Time ...
(Date:7/21/2014)... PORTLAND, Oregon , July 21, 2014 /PRNewswire/ ... by Allied Market Research titled, "Global biosimilars/follow-on-biologics market ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... that the global biosimilars market would reach $35 ... in 2013. Deeper penetration with clearer regulatory pathways ...
(Date:7/21/2014)... By order of the U.S. Bankruptcy Court, Tiger Group,s Remarketing ... optical equipment, designer eyeglass frames, and other assets of ... LLC. Online bidding opens July 21 at ... style, on July 28 beginning at 10:30 a.m. (ET). Previews ... 25 th and 26 th at 12 locations ...
Breaking Medicine Technology:Thoratec Schedules Second Quarter Conference Call, Webcast 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4Auction Set For Assets Of National Optical Services Company 2
... Manufacturing - Has Potential to Address Gaps in Global ... World Health Organization Meeting on Evaluation of Pandemic Influenza ... NVAX ) announced favorable results from the second ... its pandemic influenza virus-like particle (VLP) vaccine candidate. ...
... Scientists announced today the,publication of a landmark peer-reviewed ... Stem Cell Journal which outlines the long term ... neural stem cells for the,treatment of Parkinson,s disease. ... FACS, "We have documented the first successful adult,neural ...
Cached Medicine Technology:Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 2Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 3Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 4Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 5Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 2Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease 3
(Date:7/22/2014)... 22, 2014 Cumberland Pediatric Dentistry ... dental experience that values anxiety-free dental care for children, ... for a child's dental care. , The orthodontic ... care to infants, adolescents, adults and those with special ... physical disability, or require unique care, such as cleft ...
(Date:7/22/2014)... 2014 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced today ... customer since 2007, has upgraded to NOVAtime ... state-of-the-art, web-based time and attendance / workforce management ... is a human services agency that provides support ...
(Date:7/22/2014)... Colorado (PRWEB) July 22, 2014 CareTouch ... called CareTouch in the Community . CareTouch employees ... year, and provide hands-on support in line with their ... improve their health. The program’s first cause is Hike ... Hospice. , On Sunday, September 14, the CareTouch ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... Group are now offering robotic assisted laser therapy ... best solutions for men and women suffering from ... procedure they now offer Follicular Unit Extraction (FUE) ... medical robot. With this new technology, their doctors ...
(Date:7/22/2014)... 22, 2014 The physical demands of ... plyometrics, powerlifting, gymnastics, kettleball lifting, calisthenics, and strongman exercises ... Jason Sobzcak, co-owner of CrossFit East Cobb, ... because extreme workouts like these require high quality supplementation. ... I need to take in about 160 grams of ...
Breaking Medicine News(10 mins):Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 3
... to be a major complication of diabetes, despite the ... amputations are currently performed among the diabetic population. ... in the retinas of about 900 diabetic patients who ... All were followed for 20 years to assess how ...
... new study shows hydrotherapy, or water exercise, may improve strength ... Australia studied more than 100 patients with osteoarthritis who were ... The first group exercised three times a week in a ... third did not exercise at all. Both the water and ...
... Chronic lung disease is a primary long-term complication among ... are at greater risk for pulmonary hypertension and impaired ... risk of developing neurological problems. ,A new ... benefit from treatment with inhaled nitric oxide. ,Researchers ...
... pain, pelvic pressure, frequent urination or abnormal periods, uterine ... found in the uterus and can// range in size ... or larger. Now, there’s an improvement to uterine fibroid ... choice for many women. ,Sabrina Figueroa considers herself ...
... back pain is when symptoms have lasted for less ... program that includes group classes, exercise sheet// handouts, and ... their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... years, Keith Black, M.D., from Cedars-Sinai Medical Center in Los ... cancer. While his research moves forward, he’s helping patients ... tumor vaccine. Dr. Black says brain tumors ... the immune system could use to recognize the tumor. By ...
Cached Medicine News:Health News:Uterine Fibroid Embolization Gaining Popularity 2Health News:New vaccine for brain cancer 2
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Meet Galileo, the best reason to move to automation; the best way to upgrade your capabilities....
Medicine Products: